Cargando…

Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy

Tetrachlorinated phthalimide analogues bearing a boron-pinacolate ester group were synthesised via two synthetic routes and evaluated in their glycosidase modulating and anticancer properties, with a view to use them in boron neutron capture therapy (BNCT), a promising radiation type for cancer, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Campkin, David M., Shimadate, Yuna, Bartholomew, Barbara, Bernhardt, Paul V., Nash, Robert J., Sakoff, Jennette A., Kato, Atsushi, Simone, Michela I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182199/
https://www.ncbi.nlm.nih.gov/pubmed/35684388
http://dx.doi.org/10.3390/molecules27113447
_version_ 1784723976414560256
author Campkin, David M.
Shimadate, Yuna
Bartholomew, Barbara
Bernhardt, Paul V.
Nash, Robert J.
Sakoff, Jennette A.
Kato, Atsushi
Simone, Michela I.
author_facet Campkin, David M.
Shimadate, Yuna
Bartholomew, Barbara
Bernhardt, Paul V.
Nash, Robert J.
Sakoff, Jennette A.
Kato, Atsushi
Simone, Michela I.
author_sort Campkin, David M.
collection PubMed
description Tetrachlorinated phthalimide analogues bearing a boron-pinacolate ester group were synthesised via two synthetic routes and evaluated in their glycosidase modulating and anticancer properties, with a view to use them in boron neutron capture therapy (BNCT), a promising radiation type for cancer, as this therapy does little damage to biological tissue. An unexpected decarbonylation/decarboxylation to five 2,3,4,5-tetrachlorobenzamides was observed and confirmed by X-ray crystallography studies, thus, giving access to a family of borylated 2,3,4,5-tetrachlorobenzamides. Biological evaluation showed the benzamide drugs to possess good to weak potencies (74.7–870 μM) in the inhibition of glycosidases, and to have good to moderate selectivity in the inhibition of a panel of 18 glycosidases. Furthermore, in the inhibition of selected glycosidases, there is a core subset of three animal glycosidases, which is always inhibited (rat intestinal maltase α-glucosidase, bovine liver β-glucosidase and β-galactosidase). This could indicate the involvement of the boron atom in the binding. These glycosidases are targeted for the management of diabetes, viral infections (via a broad-spectrum approach) and lysosomal storage disorders. Assays against cancer cell lines revealed potency in growth inhibition for three molecules, and selectivity for one of these molecules, with the growth of the normal cell line MCF10A not being affected by this compound. One of these molecules showed both potency and selectivity; thus, it is a candidate for further study in this area. This paper provides numerous novel aspects, including expedited access to borylated 2,3,4,5-tetrachlorophthalimides and to 2,3,4,5-tetrachlorobenzamides. The latter constitutes a novel family of glycosidase modulating drugs. Furthermore, a greener synthetic access to such structures is described.
format Online
Article
Text
id pubmed-9182199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91821992022-06-10 Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy Campkin, David M. Shimadate, Yuna Bartholomew, Barbara Bernhardt, Paul V. Nash, Robert J. Sakoff, Jennette A. Kato, Atsushi Simone, Michela I. Molecules Article Tetrachlorinated phthalimide analogues bearing a boron-pinacolate ester group were synthesised via two synthetic routes and evaluated in their glycosidase modulating and anticancer properties, with a view to use them in boron neutron capture therapy (BNCT), a promising radiation type for cancer, as this therapy does little damage to biological tissue. An unexpected decarbonylation/decarboxylation to five 2,3,4,5-tetrachlorobenzamides was observed and confirmed by X-ray crystallography studies, thus, giving access to a family of borylated 2,3,4,5-tetrachlorobenzamides. Biological evaluation showed the benzamide drugs to possess good to weak potencies (74.7–870 μM) in the inhibition of glycosidases, and to have good to moderate selectivity in the inhibition of a panel of 18 glycosidases. Furthermore, in the inhibition of selected glycosidases, there is a core subset of three animal glycosidases, which is always inhibited (rat intestinal maltase α-glucosidase, bovine liver β-glucosidase and β-galactosidase). This could indicate the involvement of the boron atom in the binding. These glycosidases are targeted for the management of diabetes, viral infections (via a broad-spectrum approach) and lysosomal storage disorders. Assays against cancer cell lines revealed potency in growth inhibition for three molecules, and selectivity for one of these molecules, with the growth of the normal cell line MCF10A not being affected by this compound. One of these molecules showed both potency and selectivity; thus, it is a candidate for further study in this area. This paper provides numerous novel aspects, including expedited access to borylated 2,3,4,5-tetrachlorophthalimides and to 2,3,4,5-tetrachlorobenzamides. The latter constitutes a novel family of glycosidase modulating drugs. Furthermore, a greener synthetic access to such structures is described. MDPI 2022-05-26 /pmc/articles/PMC9182199/ /pubmed/35684388 http://dx.doi.org/10.3390/molecules27113447 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Campkin, David M.
Shimadate, Yuna
Bartholomew, Barbara
Bernhardt, Paul V.
Nash, Robert J.
Sakoff, Jennette A.
Kato, Atsushi
Simone, Michela I.
Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title_full Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title_fullStr Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title_full_unstemmed Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title_short Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy
title_sort borylated 2,3,4,5-tetrachlorophthalimide and their 2,3,4,5-tetrachlorobenzamide analogues: synthesis, their glycosidase inhibition and anticancer properties in view to boron neutron capture therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182199/
https://www.ncbi.nlm.nih.gov/pubmed/35684388
http://dx.doi.org/10.3390/molecules27113447
work_keys_str_mv AT campkindavidm borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT shimadateyuna borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT bartholomewbarbara borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT bernhardtpaulv borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT nashrobertj borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT sakoffjennettea borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT katoatsushi borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy
AT simonemichelai borylated2345tetrachlorophthalimideandtheir2345tetrachlorobenzamideanaloguessynthesistheirglycosidaseinhibitionandanticancerpropertiesinviewtoboronneutroncapturetherapy